The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Guest Editorial

California Institute of Regenerative Medicine and Cancer Research: A promise broken?

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Approximately 21 years ago, I had the privilege of working and helping to pass Proposition 71, which authorized $3 billion dollars in state bonds to fund stem cell research in California. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Stephen J. Forman, MD
Director, Hematologic Malignancies Research Institute, Professor, Department of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Therapeutics Research Laboratory, Co-director, Hematologic Malignancies Program, City of Hope Comprehensive Cancer Center; Professor, Department of Medical Oncology & Therapeutics Research, City of Hope
Table of Contents

YOU MAY BE INTERESTED IN

Sponsored

The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer.

Congress settled the FY26 question in February, with NCI receiving $7.352 billion, an increase of $128 million over the prior year. After a year in which cancer center directors spent an extraordinary share of their leadership attention defending the research enterprise, that outcome deserves to be called what it was: a win.
By Jeff Sorenson
In Brief

UCLA researchers receive $7M NIH grant to launch trial for immunotherapy-related diabetes

UCLA researchers have received a grant worth up to $7 million over five years from the National Institute of Allergy and Infectious Diseases to launch a first-in-human clinical trial evaluating whether drugs already used to treat autoimmune diseases can prevent or reverse immune checkpoint inhibitor-induced type 1 diabetes, a rare but often permanent complication of cancer immunotherapy.
Byline
Stephen J. Forman, MD
Director, Hematologic Malignancies Research Institute, Professor, Department of Hematology & Hematopoietic Cell Transplantation, Director, T Cell Therapeutics Research Laboratory, Co-director, Hematologic Malignancies Program, City of Hope Comprehensive Cancer Center; Professor, Department of Medical Oncology & Therapeutics Research, City of Hope
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account